Search alternatives:
largest decrease » larger decrease (Expand Search), marked decrease (Expand Search)
values decrease » values increased (Expand Search)
large decrease » larger decrease (Expand Search), marked decrease (Expand Search), large increases (Expand Search)
ct values » _ values (Expand Search), i values (Expand Search)
b largest » _ largest (Expand Search), b large (Expand Search)
c large » _ large (Expand Search), a large (Expand Search), b large (Expand Search)
Showing 121 - 140 results of 1,084 for search '(( ct values decrease ) OR ((( b largest decrease ) OR ( c large decrease ))))', query time: 0.62s Refine Results
  1. 121
    Antibody and antigen responses to Ensovibep vs placebo day 1–90.

    Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  2. 122
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  3. 123
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  4. 124
    Overview of the six original ACTIV-3/TICO trials.

    Overview of the six original ACTIV-3/TICO trials. by Elizabeth S. Munroe (21568166)

    Published 2025
    “…However, there is concern that by neutralizing the SARS-CoV-2 virus, nMAbs may decrease the availability of antigens to the immune system, potentially impairing the endogenous polyclonal immune response and decreasing long-term immune protection.…”
    Save to List
    Saved in:
  5. 125
    Baseline patient characteristics across neutralizing monoclonal antibody trials.

    Baseline patient characteristics across neutralizing monoclonal antibody trials. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  6. 126
    Antibody and antigen responses to Lufotrelvir vs placebo day 1–90.

    Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  7. 127
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  8. 128
    Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity.

    Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  9. 129
    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis).

    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  10. 130
    Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies.

    Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  11. 131
    Long-term anti-nucleocapsid response by baseline patient characteristics.

    Long-term anti-nucleocapsid response by baseline patient characteristics. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  12. 132
    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis).

    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measu... by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  13. 133
    Study Flow Diagram.

    Study Flow Diagram. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  14. 134
    The heatmap of two types high alcohol use-related Stroke showing ASMR (A), ASDR (B), Age-Standardized Rate of YLDs (C), and Age-Standardized Rate of YLLs (D) across 21 GBD regions in 2021.

    The heatmap of two types high alcohol use-related Stroke showing ASMR (A), ASDR (B), Age-Standardized Rate of YLDs (C), and Age-Standardized Rate of YLLs (D) across 21 GBD regions... by Nannan Qian (10650782)

    Published 2025
    Save to List
    Saved in:
  15. 135
    ASMR (A), ASDR (B), Age-Standardized Rate of YLDs (C), and Age-Standardized Rate of YLLs (D) of high alcohol use-related Stroke in both sexes combined in global and five SDI regions, 1990–2021.

    ASMR (A), ASDR (B), Age-Standardized Rate of YLDs (C), and Age-Standardized Rate of YLLs (D) of high alcohol use-related Stroke in both sexes combined in global and five SDI region... by Nannan Qian (10650782)

    Published 2025
    Save to List
    Saved in:
  16. 136
    The age-specific burden of high alcohol use-related Stroke, death and ASMR (A), DALYs and ASDR (B), YLDs and Age-Standardized Rate of YLDs (C), YLLs and Age-Standardized Rate of YLLs (D) globally in 2021.

    The age-specific burden of high alcohol use-related Stroke, death and ASMR (A), DALYs and ASDR (B), YLDs and Age-Standardized Rate of YLDs (C), YLLs and Age-Standardized Rate of YL... by Nannan Qian (10650782)

    Published 2025
    Save to List
    Saved in:
  17. 137
    ASMR (A), ASDR (B), Age-Standardized Rate of YLDs (C), and Age-Standardized Rate of YLLs (D) of high alcohol use-related Stroke in males and females across 21 GBD regions and SDI regions in 2021.

    ASMR (A), ASDR (B), Age-Standardized Rate of YLDs (C), and Age-Standardized Rate of YLLs (D) of high alcohol use-related Stroke in males and females across 21 GBD regions and SDI r... by Nannan Qian (10650782)

    Published 2025
    Save to List
    Saved in:
  18. 138
    Replication of YFV-17D cap1 and cap0 in C6/36 cells.

    Replication of YFV-17D cap1 and cap0 in C6/36 cells. by Anja vom Hemdt (19787189)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  19. 139
    Geographical distribution of large cities and small cities.

    Geographical distribution of large cities and small cities. by Saul Estrin (8629173)

    Published 2024
    Save to List
    Saved in:
  20. 140
    Innovation and night light in large and small cities.

    Innovation and night light in large and small cities. by Saul Estrin (8629173)

    Published 2024
    Save to List
    Saved in:

Search Tools: